Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 66

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 66
---
,249,904and 583,198and 1,249,904and 206,452, respectively. As of June 30, 2025, the PPCs issued and outstanding of 583,198consist of 14,920issued on October 9, 2024 with the Debt SPA with a stated value of $ 74,003convertible into 44,850common shares and the 568,278issued in the March 2025 SPA issuable into 568,278common shares. As of June 30, 2025, there are 1,863,032common shares issuable upon the conversion of the issued and outstanding Preferred Shares and PPCs. Pursuant to the Company’s articles of association, PPCs accrue dividends on the stated value at a rate of 8%. As of June 30, 2025, accrued dividends totaled $ 126,367which has been included in other accrued liabilities on the accompanying balance sheet. Annex A-15 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Treasury Shares per the Swiss Corporate Law The Company may hold common shares in treasury per Swiss Corporate Law and may consider issuing additional common shares to the Exchange Agent during a capital increase. Swiss law limits the Company’s right to purchase and hold its own shares. The Company and its subsidiaries may purchase shares only if and to the extent that (i) freely disposable equity capital is available in the required amount; and (ii) the combined par value of all such shares does not exceed 10% of the share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20%. The Company currently does not have any transfer restriction in its articles of association. If the Company owns shares that exceed the threshold of 10% of the Company’s share capital, the excess must be sold or cancelled by means of a capital reduction within a reasonable time. Shares held by the Company or its subsidiaries are not entitled to vote at the shareholders’ meeting but are entitled to the economic benefits applicable to the shares generally, including dividends and pre -emptiverights in the case of share capital increases. Swiss law and the Company’s articles of association do not impose any restrictions on the exercise of voting or any other shareholder rights by shareholders residing outside of Switzerland. Furthermore, according to Swiss accounting rules, the Company needs to reflect the